Platelet Gene Expression in Systemic Lupus Erythematosus and Cardiovascular Health.

Area of Science:

• Immunology
• Cardiovascular Medicine
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease associated with increased cardiovascular risks.
• Vascular dysfunction is a significant concern in SLE patients.
• Existing biomarkers may not fully capture the complexity of SLE's impact on vascular health.

Purpose of the Study:

• To validate the Systemic Lupus Erythematosus Activity Platelet-Gene Expression Signature (SLAP-GES) score.
• To assess the relationship between SLAP-GES, platelet activity, and vascular health markers in SLE.

Main Methods:

• Validation of the SLAP-GES score against established SLE disease activity metrics.
• Assessment of platelet aggregation, leukocyte-platelet aggregates, and neutrophil-platelet aggregates.
• Evaluation of glycocalyx integrity and brachial artery flow-mediated dilation.

Main Results:

• SLAP-GES demonstrated consistency over time and strong association with SLE disease activity.
• Elevated SLAP-GES correlated with increased platelet aggregation and circulating platelet-leukocyte/neutrophil aggregates.
• SLAP-GES was significantly associated with impaired glycocalyx and reduced flow-mediated dilation.

Conclusions:

• The SLAP-GES score is a validated measure of SLE disease activity.
• SLAP-GES is a potential indicator of heightened platelet activity in SLE.
• SLAP-GES is associated with vascular dysfunction, including impaired glycocalyx and endothelial function, in SLE patients.